-
-
-
-
Name Sequence (5' to 3') Usage α4 forward GAACTAGCTAGCGCATGGCTTGGGAAGCGAGa PCR amplification of human α4 from cDNA α4 reverse GCTCCTGCCTCGAGTCAATTTGAAAGAAGTCCTTAATC β7 forward GAAACACGAATTCTTGGGATCTCGGGCATGGTGG PCR amplification of human β7 from cDNA β7 reverse CCTATTCTAGAGGGTAAGTGTCCCTCCCTCCTTCAGA αE forward GAACTAGCTAGCGCTCCAGCAAGGATGTGGCTCTTC PCR amplification of human αE from cDNA αE reverse TTATGCCTCGAGTCTCCCAGTGGATAGCAGGTCC β1 forward AACGGAATTCAAGATGAATTTACAACCAATTTTCTG PCR amplification of human β1 from cDNA β1 reverse TAGCTCGTCTAGAAGTACTCATTTTCCCTCATACTTC m. α4 forward GACCTAGCTAGCTGTTGAATGTTCTCCACCAAGAGCG PCR amplification of mouse α4 from cDNA m. α4 reverse TATGCCTCGAGGTCTTCAGTCATCATTGCTTTTGCT m. β7 forward AATATGAATTCTGCTCCTCCTCAAGCACCTGCCATG PCR amplification of mouse β7 from cDNA m. β7 reverse CACCTGGTCTAGAACTGTCCTCCAAGACAAGAATCCTAAGTC r. α4forward GACCTAGCTAGCTGTTGAATGTTCCCCACCAAGAGTG PCR amplification of rat α4from cDNA r. α4reverse TTACCTCGAGAGTCTTCAGTCATCATTGCTTTTGCTGT r. β7 forward ACCTAGCTAGCGCCATGGTGGATTCATCAACTGTTC PCR amplification of rat β7 from cDNA r. β7 reverse TTACCTCGAGCTAAGTCAGTCAGCCTCCTGGGTCAG iα4 #1 forward TGCTCCGTGTTATCAAGATTATTTCAAGAGAATAATCTTGATAACACGGAGCTTTTTTG shRNA targeting α4 iα4 #1 reverse TCGACAAAAAAGCTCCGTGTTATCAAGATTATTCTCTTGAAATAATCTTGATAACACGGAGCA iα4 #2 forward TCGGGAGCAGTAATGAATGCAATTCAAGAGATTGCATTCATTACTGCTCCCGTTTTTTG shRNA targeting α4 iα4 #2 reverse TCGACAAAAAACGGGAGCAGTAATGAATGCAATCTCTTGAATTGCATTCATTACTGCTCCCGA iβ1 forward TGCCTTGCATTACTGCTGATATTTCAAGAGAATATCAGCAGTAATGCAAGGCTTTTTTC shRNA targeting β1 iβ1 reverse TCGAGAAAAAAGCCTTGCATTACTGCTGATATTTCAAGAGAATATCAGCAGTAATGCAAGGCA iCCR5 forward TGAGCATGACTGACATCTACTTCAAGAGAGTAGATGTCAGTCATGCTCTTTTTTG shRNA targeting CCR5 iCCR5 reverse TCGACAAAAAAGAGCATGACTGACATCTACTCTCTTGAAGTAGATGTCAGTCATGCTCA scrambled forward TCCTAAGGTTAAGTCGCCCTTTCAAGAGAAGGGCGACTTAACCTTAGGTTTTTTG non-targeting shRNA scrambled reverse TCGACAAAAAACCTAAGGTTAAGTCGCCCTTCTCTTGAAAGGGCGACTTAACCTTAGGA The underlined positions are ezymatic restriction sites, sense or anti-sense sequences of the oligos as implicated. Table 1. Primers and shRNA oligos
Figure 3 个
Table 1 个